Foghorn Therapeutics Inc. - Common Stock, $0.0001 par value per share (FHTX)

CUSIP: 344174107

Q1 2023 13F Holders as of 31 Mar 2023

Holder snapshot 7 signals
Share change
+157,650
Put/Call ratio
560%
SEC-reported price per share
$6.20
Indexed holders
61
Value change
+$937,198
Number of buys
24
Open additional details 1 more signal available
Number of sells
24
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
59,489,510

Security key

344174107

Report period

Q1 2023

Indexed institutions

61

Top holders

10

Ownership snapshot

Top reported holders of FHTX - Foghorn Therapeutics Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Flagship Pioneering, LLC
Disclosed value leader
Flagship Pioneering, LLC
Comparable rows
0/15
Latest evidence
31 Dec 2022
13F 3/4/5 Highest disclosed value: $80,860,886 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Flagship Pioneering, LLC has the largest disclosed position value at $80.86M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Flagship Pioneering, LLC's linked filing trail.
Disclosed position value Top 5
Flagship Pioneering, LLC $80.86M
Cigall Kadoch $29.94M
Artal Group S.A. $10.98M
Euclidean Capital LLC $8.05M
BlackRock Finance, Inc. $7.98M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Flagship Pioneering, LLC
13F
Company
13F
—
denominator unverified
$80,860,886
12,674,120 shares
— 31 Dec 2022
Cigall Kadoch
3/4/5
Director
—
mixed-class rows
$29,939,469
3,636,909 shares
mixed-class rows
— 31 Aug 2022
Artal Group S.A.
13F
Company
13F
—
denominator unverified
$10,978,000
1,720,720 shares
— 31 Dec 2022
Euclidean Capital LLC
13F
Company
13F
—
denominator unverified
$8,046,845
1,261,261 shares
— 31 Dec 2022
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$7,975,178
1,250,028 shares
— 31 Dec 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$6,494,126
1,017,888 shares
— 31 Dec 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
61
Shares
26,253,067
Indexed holders
61
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2023 vs Q4 2022 Across Filers

Q4 2022 indexed holders
63
Q1 2023 indexed holders
61
Indexed holder difference
-2
Investor Q4 2022 Shares Q1 2023 Shares Share Diff Share Chg % Q4 2022 value Q1 2023 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .